American Academy of Neurology

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
Wednesday, April 3, 2024
Athira Pharma, HGF, AAN, Nervous system, ALS, American Academy, Annual general meeting, American Academy of Neurology, Pharmaceutical industry

BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online.

Key Points: 
  • BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online.
  • The presentation will highlight preclinical data supporting the continued development of Athira's pipeline of small molecule candidates targeting the neurotrophic hepatocyte growth factor (HGF) system, including fosgonimeton for Alzheimer’s disease, ATH-1105 for amyotrophic lateral sclerosis (ALS), and ATH-1020 for Parkinson’s disease.
  • Athira’s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the nervous system.
  • Athira’s drug candidates have distinct properties, which the company believes may be applicable to a broad range of neurodegenerative diseases.

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Microglia, American Academy, American Academy of Neurology, ALSP, AAN, Poster

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.

Key Points: 
  • WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.
  • Details of the oral presentation are as follows:
    Title: Interim Results on VGL101 From IGNITE: First Interventional Phase 2 Study in Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
    Details of the poster presentations are as follows:
    Presented by: David S. Lynch, M.D., Ph.D., National Hospital for Neurology & Neurosurgery; University College London Institute of Neurology

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Friday, March 8, 2024
American Academy of Neurology, MD, Mount Sinai Hospital, USF, Multiple sclerosis, AAN, Abstract (summary), University, Therapy, Patient, RMS, Publication, American Academy, Harbor

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.

Key Points: 
  • NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
  • Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49 .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

CMS Includes the Patient Activation Measure in its Merit-Based Incentive Payment System Starting in 2024

Retrieved on: 
Friday, December 1, 2023
Health, Practice Management, Health Technology, Other Health, Health Insurance, Managed Care, General Health, Patient-centered outcomes, ANA, National Kidney Foundation, NKF, ASN, Organization, National Alliance, White, AHIP, Elective surgery, Kidney disease, ACC, American Society of Nephrology, American Academy, American Diabetes Association, Patient, American Occupational Therapy Association, PAM, University, American Nurses Association, American Academy of Neurology, CMS, Patient Activation Measure, AAOS, Doctor of Public Health, NAMI, Doctor of Philosophy, Medicare, Society, AAN, Mental disorder, MVP Arena, AOTA, Human, Nursing, MIPS, Phreesia

The Patient Activation Measure (PAM) measures a patient’s knowledge, skills and confidence to self-manage their health.

Key Points: 
  • The Patient Activation Measure (PAM) measures a patient’s knowledge, skills and confidence to self-manage their health.
  • Activated patients feel comfortable advocating for themselves and asking for support from their care team to manage their own health.
  • “It’s incredibly gratifying to see CMS include the Patient Activation Measure Performance Measure in its program as a high priority outcome measure.
  • “As a practice that uses the Patient Activation Measure and participates in MIPS, we're incredibly excited to see that PAM will be a MIPS measure going forward.

Groundbreaking study reveals link between air pollution and incidence of Parkinson’s disease

Retrieved on: 
Tuesday, October 31, 2023
Dignity, Research, The Michael J. Fox Foundation, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Medicare, Dignity Health St. Joseph's Hospital and Medical Center, Pesticide, Air pollution, Doctor of Philosophy, Inflammation, National Institute of Environmental Health Sciences, Medical Center, Barrow Neurological Institute, Risk, Cell death, American Academy, Particulates, Brain, Hospital, American Academy of Neurology, Pharmaceutical industry, Agriculture, Neurology

“Regional differences in Parkinson’s disease might reflect regional differences in the composition of the particulate matter.

Key Points: 
  • “Regional differences in Parkinson’s disease might reflect regional differences in the composition of the particulate matter.
  • The population-based geographic study identified nearly 90k people with Parkinson’s disease from a Medicare dataset of nearly 22-million.
  • Those identified with having Parkinson’s disease were geocoded to the neighborhood of residence, enabling researchers to calculate the rates of Parkinson’s disease within each region.
  • Researchers hope the data from this novel study will help enforce stricter policies that will lower air pollution levels and decrease the risk for Parkinson’s disease and other associated illnesses.

Brain Injury Expert Says Important Changes Still Needed to Law Defining Death Despite Reform Pause

Retrieved on: 
Thursday, October 26, 2023
Uniform Law Commission, Society of Critical Care Medicine, American Academy of Pediatrics, Death, Neurosurgery, Physician, Human, Medicine, MD, Uniform Determination of Death Act, NYU Langone Health, Organization, Brain, Orthodox Judaism, NYU, Critical Care Medicine (journal), American Academy, New York University Grossman School of Medicine, Society, Nursing care plan, Coma, Brain death, Euthanasia, American Academy of Neurology, Medical device, Pharmaceutical industry, Neurology

The recently announced pause by the Uniform Law Commission, which is spearheading revisions, is disappointing, the expert notes, but should not permanently stall practical fixes to longstanding problems with the Death Act.

Key Points: 
  • The recently announced pause by the Uniform Law Commission, which is spearheading revisions, is disappointing, the expert notes, but should not permanently stall practical fixes to longstanding problems with the Death Act.
  • Lewis says her survey results showed that 34 organizations (83%) favored revisions to the Death Act.
  • Uniform Determination of Death Act, which defined death as either the irreversible cessation of all brain or cardiopulmonary functions.
  • However, such loss of hormone function is not needed to be declared dead by brain criteria using current medical standards.

$10 Million Research Initiative Established to Understand Neuroinflammation's Impact on Broad Range of Brain Diseases

Retrieved on: 
Tuesday, October 17, 2023
Diagnosis, Parkinson's disease, 2018 Chinese Super League, ALS, Schizophrenia, NFLPA, COVID-19, DSM-IV codes, MS, Stroke, NFL, Brain damage, American Academy, Brain, Dementia, Myenteric plexus, The Encephalitis Society, Ageing, Alzheimer's disease, Movement, Nervous system, Encephalitis, National Football League Players Association, American Academy of Neurology, Speech, Immune system, Multiple sclerosis, Infection, Neuroscience, Inflammation, Neuroinflammation, Life, Spectrum, Research, Pharmaceutical industry, Vaccine, Medical device, Neurology

The research initiative is part of the American Brain Foundation's existing Cure One, Cure Many program , which promotes innovative, cross-cutting approaches to brain disease diagnosis and treatment.

Key Points: 
  • The research initiative is part of the American Brain Foundation's existing Cure One, Cure Many program , which promotes innovative, cross-cutting approaches to brain disease diagnosis and treatment.
  • This large-scale, multi-phased initiative will support research to better understand how neuroinflammation acts as an underlying mechanism across nearly all brain diseases and affects people of all ages.
  • "The research funded by the initiative will impact diseases as widespread and different as Parkinson's, encephalitis, multiple sclerosis (MS), Alzheimer's, brain trauma, autism, and others."
  • The American Brain Foundation will begin soliciting research proposals for the neuroinflammation initiative in spring 2024, and research will begin in 2025.

New Guidance Issued on the Determination of Brain Death AAN, AAP, CNS and SCCM Develop Consensus Practice Guideline

Retrieved on: 
Thursday, October 12, 2023
Comatose, Nursing care plan, Guideline, Hospital, Society of Critical Care Medicine, Doctor of Philosophy, NYU Langone Health, Death, Boston University, Brain death, American Academy, Brain, FAAN, American Academy of Pediatrics, American Academy of Neurology, Neurology, AAP, AAN, Stanford University, University, Philadelphia, Society, Pediatrics (journal), Health, Einstein Medical Center Philadelphia, SCCM, Critical Care Medicine (journal), CNS, Patient, Pharmaceutical industry, Dietary supplement, Medical imaging, Medical device, Nursing, Pediatrics, MD, FAAP

MINNEAPOLIS, Oct. 11, 2023 /PRNewswire/ -- New guidance has been issued for clinicians on the determination of brain death, also known as death by neurologic criteria.

Key Points: 
  • MINNEAPOLIS, Oct. 11, 2023 /PRNewswire/ -- New guidance has been issued for clinicians on the determination of brain death, also known as death by neurologic criteria.
  • This guideline updates the 2010 AAN adult practice guidelines and the 2011 AAP/CNS/SCCM pediatric practice guidelines on the determination of brain death.
  • Because of a lack of high-quality evidence on the subject, the experts used an evidence-informed consensus process to develop the guideline.
  • The consensus practice guideline outlines the standardized procedure for trained clinicians to evaluate people for brain death.

bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services

Retrieved on: 
Tuesday, September 19, 2023
Biotechnology, FDA, Other Health, Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Surgery, Genetics, Clinical Trials, COPD, DNA, Fitzsimons Army Medical Center, American Board of Psychiatry and Neurology, College, Internal medicine, Louisiana State University, Marketing, Clinical Laboratory, SARS-CoV-2, CAP, Marie Cassidy, Pathology, Lung cancer, Lead, American Academy, College of American Pathologists, BIAF, Brooke Army Medical Center, Lung, Sale, Organization, American Board of Commissioners for Foreign Missions, STI, CLIA, Acquisition, Physician, Trustee, Psychiatry, American Academy of Neurology, Maria, American Board of Pathology, Medical imaging, Nursing, Neurology

bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.
  • The laboratory assets are being acquired by a new wholly owned subsidiary of bioAffinity Technologies, Precision Pathology Laboratory Services, LLC (PPLS).
  • Precision Pathology provides pathology services to physicians practicing in a variety of outpatient settings and has offered bioAffinity Technologies’ CyPath® Lung as a laboratory developed test for the detection of early-stage lung cancer.
  • In addition to CyPath® Lung, Precision Pathology offers a range of laboratory services including respiratory testing for SARS-CoV-2 and influenza, anatomic pathology, morphological stains, histological services, DNA extractions, STI testing, and women’s and men’s health testing.

Study Finds 1 in 5 People on Medicare Travel 50 or More Miles to See a Neurologist

Retrieved on: 
Thursday, September 14, 2023
DSM-IV codes, Epilepsy, Concussion, Telehealth, Ohio State University, Migraine, Travel, American Academy of Neurology, University, AAN, Stroke, COVID-19, American Academy, MBA, Brain, Research, Multiple sclerosis, Alzheimer's disease, Doctor of Philosophy, MS, Medicare, Parkinson's disease, Nervous system, FAAN, ALS, Social media, Pharmaceutical industry, Road, Tourism, MD, Neurology

Nearly one in five people on Medicare travel 50 or more miles one way to see a neurologist.

Key Points: 
  • Nearly one in five people on Medicare travel 50 or more miles one way to see a neurologist.
  • "We also found that people who traveled long distances were less likely to return for a follow‐up visit with a neurologist."
  • The study included over 563,000 people on Medicare who saw a neurologist at least once during the one-year study.
  • People who did not travel long distances went an average distance of 13 miles with an average travel time of 22 minutes.